As nations around the world seek to reap the rewards of biosimilar savings, some countries, including Colombia, are updating their regulatory processes to better facilitate the introduction of biosimilars. A paper, recently published in the Generics and Biosimilars Initiative Journal, outlines the new landscape for biosimilar products in Colombia.
As nations around the world seek to reap the rewards of biosimilar savings, some countries, including Colombia, are updating their regulatory processes to better facilitate the introduction of biosimilars. A paper, recently published in the Generics and Biosimilars Initiative Journal, outlines the new landscape for biosimilar products in Colombia.
Prior to having a dedicated approval process for biologics and biosimilars, all steps in the approval process for any product had to be carried out sequentially, not simultaneously: A pharmacological assessment was followed by submission of documentation for legal, quality, and process information; regulatory approval of quality controls; and laboratory testing.
However, in Colombia’s new regulatory framework, 4 assessment groups will work simultaneously to assess filings for safety and efficacy, quality and process, pharmacovigilance, and quality control. After these assessments take place, regulators will meet to make a final decision on the product. If they deliver a positive decision, the drug maker must next submit an application for marketing authorization and, after receiving approval, may launch its product.
In addition to making the approval process more efficient, new regulation has created 3 pathways for the submission of biologics:
According to the authors, the pathway selected will depend upon the particular biologic drug or biosimilar molecule in question.
Reference
Esteban FJS, Cortes JAG. Regulations for biotheraputics approval in Colombia. GaBI J. 2018;7(1):26-28. doi: 10.5639/gabij.2018.0701.006.
Enhancing Adoption of Infused Biosimilars for a Sustainable Future
October 30th 2024An IQVIA report highlights challenges to the sustainability of infused biosimilars in the US, citing rebate walls and reimbursement policies, and proposes key solutions to enhance adoption and benefits for all stakeholders.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
FDA and Industry Experts Unpack Biosimilar Device Requirements
October 23rd 2024At the GRx+Biosims 2024 conference, a panel of industry experts and FDA officials discussed evolving device requirements for biosimilars and interchangeable biosimilars, highlighting new approaches to comparative use human factors studies, regulatory challenges, and alternative validation methods.
The Subcutaneous Revolution: Zymfentra and the Future of IBD Care With Dr Andres Yarur
December 17th 2023On this episode of Not So Different, Andres Yarur, MD, a researcher and associate professor of medicine at Cedars-Sinai Medical Center, discusses the significance of the FDA approval for Zymfentra, the world's first subcutaneous infliximab product, for patients with inflammatory bowel disease (IBD).
Revolutionizing Biopharmaceuticals: The EU's Biosimilar Success and Remaining Challenges
October 16th 2024The European Union's (EU) approach to biosimilars has revolutionized the biopharmaceutical market by driving innovation, lowering costs, and increasing adoption; however, there remains a need for more education, real-world evidence, and efforts to address challenges to enhance patient access and affordability.